Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Logothetis

Showing results (161-170 of 251) with videos related to

Pageof 26
Sort By:
Journal of Oncology Practice|August 15, 2013
Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measureKaren A Autio, Antonia V Bennett, Xiaoyu Jia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2015
Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate CancersAna M Aparicio, Li Shen, Elsa Li Ning Tapia, et al.
European Urology|June 10, 2019
Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus PrednisoneEleni Efstathiou, John W Davis, Louis Pisters, et al.
The Lancet. Oncology|October 1, 2013
Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trialEthan Basch, Karen Autio, Charles J Ryan, et al.
Cancers|December 23, 2023
Evaluation of the Aggressive-Variant Prostate Cancer Molecular Signature in Clinical Laboratory Improvement Amendments (CLIA) EnvironmentsPaul V Viscuse, Rebecca S Slack-Tidwell, Miao Zhang, et al.
European Journal of Cancer (Oxford, England : 1990)|September 18, 2021
Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancerNicholas Spetsieris, Myrto Boukovala, Ioannis Alafis, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 5, 2024
Prostate cancer-induced endothelial-cell-to-osteoblast transition drives immunosuppression in the bone-tumor microenvironment through Wnt pathway-induced M2 macrophage polarizationGuoyu Yu, Paul G Corn, Celia Sze Ling Mak, et al.
Biorxiv : the Preprint Server for Biology|December 11, 2023
Prostate cancer-induced endothelial-to-osteoblast transition generates an immunosuppressive bone tumor microenvironmentGuoyu Yu, Paul G Corn, Celia Sze Ling Mak, et al.
Molecular Cancer Research : MCR|January 23, 2013
Targeting constitutively activated β1 integrins inhibits prostate cancer metastasisYu-Chen Lee, Jung-Kang Jin, Chien-Jui Cheng, et al.
The Lancet. Oncology|September 14, 2019
Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trialPaul G Corn, Elisabeth I Heath, Amado Zurita, et al.
Pageof 26

Showing results (161-170 of 251) with videos related to

Sort By:
Pageof 26
Journal of Oncology Practice|August 15, 2013
Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measureKaren A Autio, Antonia V Bennett, Xiaoyu Jia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2015
Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate CancersAna M Aparicio, Li Shen, Elsa Li Ning Tapia, et al.
European Urology|June 10, 2019
Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus PrednisoneEleni Efstathiou, John W Davis, Louis Pisters, et al.
The Lancet. Oncology|October 1, 2013
Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trialEthan Basch, Karen Autio, Charles J Ryan, et al.
Cancers|December 23, 2023
Evaluation of the Aggressive-Variant Prostate Cancer Molecular Signature in Clinical Laboratory Improvement Amendments (CLIA) EnvironmentsPaul V Viscuse, Rebecca S Slack-Tidwell, Miao Zhang, et al.
European Journal of Cancer (Oxford, England : 1990)|September 18, 2021
Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancerNicholas Spetsieris, Myrto Boukovala, Ioannis Alafis, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 5, 2024
Prostate cancer-induced endothelial-cell-to-osteoblast transition drives immunosuppression in the bone-tumor microenvironment through Wnt pathway-induced M2 macrophage polarizationGuoyu Yu, Paul G Corn, Celia Sze Ling Mak, et al.
Biorxiv : the Preprint Server for Biology|December 11, 2023
Prostate cancer-induced endothelial-to-osteoblast transition generates an immunosuppressive bone tumor microenvironmentGuoyu Yu, Paul G Corn, Celia Sze Ling Mak, et al.
Molecular Cancer Research : MCR|January 23, 2013
Targeting constitutively activated β1 integrins inhibits prostate cancer metastasisYu-Chen Lee, Jung-Kang Jin, Chien-Jui Cheng, et al.
The Lancet. Oncology|September 14, 2019
Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trialPaul G Corn, Elisabeth I Heath, Amado Zurita, et al.
Pageof 26